Office of Commercialization and Economic Development
Office of Technology Commercialization

Cell Line: Human Cystic Fibrosis Cell Line - ?F508

Technology #05-0054

The ΔF508 mutation is a three-base pair deletion in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) found in one out of 30 Caucasians and is the leading cause of CF. These growth-enhanced cell lines were created by introducing Bmi-1, a protooncogene that maintains stem cells, and hTERT, the catalytic subunit of telomerase, into three non-CF and three CF human bronchial epithelial cell preparations. The cell line may be used to evaluate how the molecular mechanisms which are responsible for CF result in clinical symptoms and to test pharmacological and gene therapy agents for efficacy in treating CF lung disease.

If you are an academic institution or nonprofit organization interested in this research tool for noncommercial purposes, please contact the researcher directly to inquire about availability.

Related Publications: